Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: Final results and biomarker analyses from the phase III COSMIC-313 study

Authors

• R J Motzer, Memorial Sloan Kettering Cancer Center
• M A Reimers, Washington University School of Medicine in St. Louis
• et al.

Journal

Annals of Oncology

Publication Date

6-1-2026

Volume

37

Issue

6

First Page

861

Last Page

871

Document Type

Open Access Publication

DOI

10.1016/j.annonc.2026.02.011

Rights and Permissions

Motzer RJ, Albiges L, Treviño Aguirre SA, Kanesvaran R, Centkowski P, Reimers MA, Sade JP, Pouessel D, Biscaldi E, Esteban E, Arranz Arija JÁ, Tykodi SS, van Kooten Losio M, Dighe A, Ma H, Valmeekam V, Simmons A, Scheffold C, Andrianova S, Braun DA, Powles T, Choueiri TK. Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: final results and biomarker analyses from the phase III COSMIC-313 study. Ann Oncol. 2026 Jun;37(6):861-871. doi: 10.1016/j.annonc.2026.02.011. © 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology. Thisis an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Recommended Citation

Motzer, R J; Reimers, M A; and et al., "Cabozantinib plus nivolumab and ipilimumab in previously untreated, advanced renal cell carcinoma: Final results and biomarker analyses from the phase III COSMIC-313 study." Annals of Oncology. 37, 6. 861 - 871. (2026).
https://digitalcommons.wustl.edu/oa_4/6822

Department

ICTS (Institute of Clinical and Translational Sciences)

Additional Links

Supplemental material is available for this article at publisher site.